Cited by 402Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record.

Endocrine Treatment of Breast Cancer in Women

SANTEN, RICHARD J., MANNI, ANDREA, HARVEY, HAROLD, REDMOND, CAROL·1990·Endocrine Reviews

Open this paper in CoChat — free account

Abstract

Hormonal therapy for breast carcinoma began with the observation by George Beatson (1) in 1898 that bilateral oophorectomy caused tumor regression in selected premenopausal patients. Huggins and Bergenstal (2) later introduced surgical adrenalectomy as a form of hormone ablative treatment for postmenopausal women. To these methods were added surgical hypophysectomy and hormonal additive therapies such as the use of androgens, estrogens, progestins, and glucocorticoids (3). Since only one-third of patients experienced objective tumor regression with any of these hormonal therapies, clinicians began to favor use of cytotoxic chemotherapies in the 1960s and 1970s. During this time multiple chemotherapeutic regimens were developed which gained wide acceptance and enthusiastic support (3). However, when hormone receptor measurements were introduced in the mid-1970s, better selection of patients with hormonally responsive tumors became possible, and new impetus was provided for optimizing hormonal therapies. These developments led to the accumulation of a large body of clinical data regarding hormonal agents and provided clinicians with a broad armamentarium for the treatment of patients at the present time. We will summarize this information with the goals of highlighting specific endocrinological aspects of breast cancer treatment and providing practical perspective for choosing among various agents. Where recent comprehensive reviews are readily available, only pertinent concepts are highlighted.

Integrity signals

Registry

Crossref · 10.1210/edrv-11-2-221

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth
Nakshatri, H., Bhat‐Nakshatri, P., Martin, D. A., Goulet, R. J., & Sledge, G. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3629 · Cited by 818
“Numerous experimental and clinical studies have established that estrogen plays a major role in the initiation and progression of breast cancers (37, 44, 49).”
Background
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P. J., Bonnefoi, H. R., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G. M., Bergh, J. C. S., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 822
Skeletal Effects of Estrogen*
Turner, R. T., Riggs, B. L., & Spelsberg, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 758
Basic Guide to the Mechanisms of Antiestrogen Action
MacGregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 698
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Dombernowsky, P., Smith, I. E., Falkson, G., Leonard, R. C., Panasci, L., Joaquim Bellmunt, B., Bezwoda, W. R., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 629
Aromatase Inhibitors in the Treatment of Breast Cancer
Brueggemeier, R. W., Hackett, J. C., & Díaz‐Cruz, E. S. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0015 · Cited by 492
“Numerous clinical trials performed since the early 1980s have demonstrated the clinical efficacy of combination therapy of aminoglutethimide with corticosteroid replacement (96, 119) in treatment of hormonedependent breast cancer.”
Background
History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target
Santen, R. J., Brodie, H. J., Simpson, E. R., Siiteri, P. K., & Brodie, A. M. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0016 · Cited by 447
Self-citation
Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials
Klijn, J. G. M., Blamey, R. W., Boccardo, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.343 · Cited by 427
Botanicals in Cancer Chemoprevention
Park, E., & Pezzuto, J. M. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1021254725842 · Cited by 403
Estrogen Receptors: Bioactivities and Interactions with Cell Signaling Pathways1
Katzenellenbogen, B. S. (1996) · Biology of Reproduction · doi:10.1095/biolreprod54.2.287 · Cited by 369
Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate
Buzdar, A. U., Douma, J. A. J., Davidson, N., Elledge, R. M., Morgan, M., Smith, R., Porter, L., Nabholtz, J., Xiang, X., & Brady, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3357 · Cited by 362
p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiationPreprint
Kraus, W. L., & Kadonaga, J. T. (1998) · Genes & Development · doi:10.1101/gad.12.3.331 · Cited by 334
“TOT is a nonsteroidal triphenylethylene derivative that has partial agonist activity in some assays, whereas ICI is a steroidal compound with pure antagonist activity (Santen et al. 1990; Wakeling 1990; McDonnell et al. 1995).”
Background
A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription.
Bulun, S. E., Price, T. M., Aitken, R. J., Mahendroo, M., & Simpson, E. R. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.6.8117355 · Cited by 334
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
Masamura, S., Santner, S. J., Heitjan, D. F., & Santen, R. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.10.7559875 · Cited by 307
Self-citation
An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
Montano, M. M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P. G. V., & Katzenellenbogen, B. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6947 · Cited by 297
Molecular Mechanisms of Estrogen Action: Selective Ligands and Receptor Pharmacology
Katzenellenbogen, B. S., Choi, I., Delage-Mourroux, R., Ediger, T. R., Martini, P. G. V., Montano, M., Sun, J., Weis, K., & Katzenellenbogen, J. A. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00104-7 · Cited by 289
Aromatase Inhibitors for Ovulation Induction
Casper, R. F., & Mitwally, M. F. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1923 · Cited by 272
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
Gershanovich, M., Chaudri, H. A., Campos, D., Lurie, H., Bonaventura, A., Jeffrey, M., Buzzi, F., Bodrogi, I., Ludwig, H., Reichardt, P., et al. (1998) · Annals of Oncology · doi:10.1023/a:1008226721932 · Cited by 255
Hypothalamic Hormones and Cancer
Schally, A. V., Comaru-Schally, A. M., Nagy, A., Kovács, M., Szepesházi, K., Plonowski, A., Varga, J. L., & Halmos, G. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0217 · Cited by 279
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
Jonat, W., Howell, A., BLOMQVIST, C. P., EIERMANN, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H. H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
“Aminoglutethimide, a non-selective aromatase inhibitor, is associated with a high incidence of side-effects such as lethargy and rash and is often given alongside corticosteroid supplementation [2,8,9].”
BackgroundResult
Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study
Klijn, J. G. M. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.903 · Cited by 247
Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice.
Ju, Y. H., Doerge, D. R., Allred, K. F., Allred, C. D., & Helferich, W. G. (2002) · PubMed · Cited by 235
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis☆
Schally, A. V. (1999) · Peptides · doi:10.1016/s0196-9781(99)00130-8 · Cited by 216
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes.
Musgrove, E. A., Lee, C. S., & Sutherland, R. L. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5032 · Cited by 175
A new era in ovulation induction
Holzer, H., Casper, R., & Tulandi, T. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.078 · Cited by 194
Aromatase inhibitors: the next generation of therapeutics for endometriosis?
Attar, E., & Bulun, S. E. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.09.064 · Cited by 184
Activation of the somatotropic axis by testosterone in adult males: evidence for the role of aromatization
Weissberger, A. J., & Ho, K. K. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501143 · Cited by 185
Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy
Ishibashi, H., Suzuki, T., Suzuki, S., Niikawa, H., Lu, L., Miki, Y., Moriya, T., Hayashi, S., Handa, M., Kondo, T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3087 · Cited by 178
“Progesterone treatment is an established endocrine therapy in human hormone-dependent breast (9) and endometrial cancers (40), and at present, oral progestins such as medroxyprogesterone acetate are widely employed.”
Background
Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cellsin Vivo1
Shim, W.-S., Conaway, M. R., Masamura, S., Yue, W., Wang, J.-P., Kumar, R., & Santen, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.1.7270 · Cited by 168
Self-citation
Use of aromatase inhibitors in breast carcinoma.
Santen, R. J., & Harvey, H. A. (1999) · Endocrine Related Cancer · doi:10.1677/erc.0.0060075 · Cited by 163
“When aminoglutethimide was combined with a corticosteroid such as hydrocortisone, the regimen produced durable clinical responses in 30-50% of patients (Santen et al. 1990).”
BackgroundMethodResultInfluentialSelf-citation
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer
Klijn, J. G. M. (2000) · Steroids · doi:10.1016/s0039-128x(00)00195-1 · Cited by 157
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
Elisaf, M., Bairaktari, E. T., Nicolaides, C., Kakaidi, B., Tzallas, C., Katsaraki, A., & Pavlidis, N. A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00155-1 · Cited by 150
Identification and Assessment of Endocrine Disruptors: Limitations of in Vivo and in Vitro Assays
Zacharewski, T. R. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106577 · Cited by 163
BCAR1, a Human Homologue of the Adapter Protein p130Cas, and Antiestrogen Resistance in Breast Cancer Cells
Brinkman, A., van der Flier, S., Kok, E. M., & Dorssers, L. C. J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.112 · Cited by 146
Inhibition of aromatase activity by flavonoids
Jeong, H. J., Shin, Y. G., Kim, I. H., et al. (1999) · Archives of Pharmacal Research · doi:10.1007/bf02976369 · Cited by 143
Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer
Martens, J. W. M., Nimmrich, I., Koenig, T. W., Look, M. P., Harbeck, N., Model, F., Kluth, A., Vries, J. B., Sieuwerts, A. M., Portengen, H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0064 · Cited by 143
“Yet, progression is inevitable in these patients because recurrent breast cancer in distant metastatic sites is not a curable disease (2, 3).”
Background
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells
Watts, C. K. W., Sweeney, K. J. E., Warlters, A., Musgrove, E. A., & Sutherland, R. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00689680 · Cited by 131
“The in vitro data suggesting competitive action at E R is corroborated by a large body of clinical evidence (recently reviewed in [41]).”
Novel Progesterone Target Genes Identified by an Improved Differential Display Technique Suggest That Progestin-induced Growth Inhibition of Breast Cancer Cells Coincides with Enhancement of Differentiation
Kester, H. A., van der Leede, B. M., van der Saag, P. T., & van der Burg, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16637 · Cited by 129
Mechanisms of Cyclin-Dependent Kinase Inactivation by Progestins
Musgrove, E. A., Swarbrick, A., Lee, C. S. L., Cornish, A. L., & Sutherland, R. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.1812 · Cited by 123
“Nevertheless, synthetic progestins have an established role in the therapy of both breast and endometrial cancers (46, 49, 60).”
Background
Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors
Santen, R. J., Stuenkel, C. A., Davis, S. R., Pinkerton, J. V., Gompel, A., & Lumsden, M. A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01138 · Cited by 128
Self-citation
MVLN Cells: A bioluminescent MCF-7-derived cell line to study the modulation of estrogenic activity
Demirpençe, E., Duchesne, M., Badia, É., Gagne, D., & Pons, M. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90225-l · Cited by 126
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity
Santen, R. J., Song, R., Zhang, Z., Kumar, R., Jeng, M. H., Masamura, A., Lawrence, J., Berstein, L. M., & Yue, W. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01018 · Cited by 125
“Premenopausal women with advanced hormone-dependent breast cancer experience objective tumor regression in response to surgical oophorectomy which lowers estradiol levels from mean levels of approximately 200 pg/ml to 10 pg/ml (Santen et al. 1990).”
BackgroundSelf-citation
Role of the androgen receptor in human breast cancer.
Birrell, S. N., Hall, R. E., & Tilley, W. D. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018730519839 · Cited by 124
Aromatase inhibitors for the treatment of infertility
Mitwally, M. F., & Casper, R. F. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.3.353 · Cited by 120
“The main sources of circulating oestrogens are the ovaries in premenopausal women and adipose tissue in postmenopausal women [53,54].”
Background
Aromatase research and its clinical significance.
Czajka-Oraniec, I., & Simpson, E. R. (2010) · PubMed · Cited by 116
RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice
Velde, P. V. D., Nique, F., Bouchoux, F., Brémaud, J., HAMEAU, M., Lucas, D., Moratille, C., Viet, S., Philibert, D., & Teutsch, G. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90144-9 · Cited by 115
The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion.
Wiebe, J. P., Muzia, D., Hu, J. J., Szwajcer, D., Hill, S. A., & Seachrist, J. L. (2000) · PubMed · Cited by 114
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
Atalay, G., Biganzoli, L., Renard, F., Paridaens, R., Čufer, T., Coleman, R. E., Calvert, H., Gamucci, T., Minisini, A. M., Therasse, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00601-4 · Cited by 111
Antiestrogens: Mechanisms and actions in target cells
Katzenellenbogen, B. S., Montano, M. M., Goff, P. L., Schodin, D. J., Kraus, W. L., Bhardwaj, B., & Fujimoto, N. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00084-d · Cited by 107
Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells.
Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., & Tilley, W. D. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00109-4 · Cited by 110
Estrogen Withdrawal-Induced NF-κB Activity and Bcl-3 Expression in Breast Cancer Cells: Roles in Growth and Hormone Independence
Pratt, M. A. C., Bishop, T. E., White, D. M., Yasvinski, G., Ménard, M., Niu, M. Y., & Clarke, R. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.19.6887-6900.2003 · Cited by 110
“About 60% of all diagnosed breast cancers express estrogen receptors (ERs), and about half of these are dependent on estrogen for growth and are initially responsive to endocrine therapy (15, 25, 48).”
Background
Regulation of aromatase expression in human tissues
Bulun, S. E., & Simpson, E. R. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682738 · Cited by 105
Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.
van Agthoven, T., van Agthoven, T. L., Portengen, H., et al. (1992) · PubMed · Cited by 106
Progesterone metabolites in breast cancer
Wiebe, J. P. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01010 · Cited by 104
“Some reports indicated stimulation (Anderson et al. 1989), while others observed regression of, or no effect on, human tumors (Horwitz et al. 1985, Santen et al. 1990) resulting from treatment with P or synthetic progestins.”
Background
Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways
Katzenellenbogen, B. S. (2000) · Journal of the Society for Gynecologic Investigation · doi:10.1016/s1071-5576(99)00058-1 · Cited by 103
Use of the Aromatase Inhibitor Letrozole for Ovulation Induction in Women With Polycystic Ovarian Syndrome
Casper, R. F., & Mitwally, M. F. (2011) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182353d0f · Cited by 99
“5mg/d), inhibits estrogen levels by up to 99%.(21) Aromatase inhibitors are completely absorbed after oral administration with a mean terminal half-life of approximately 45 hours and with clearance from the systemic circulation mainly by the liver.”
Background
Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer
Reddy, J., & Oktay, K. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.09.022 · Cited by 99
“Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al. American Society of Clinical Oncology technology assessment on the use of AIs as adjuvant therapy for womenwith hormone receptor-positive breast cancer: status report.”
BackgroundInfluential
Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells
Jeng, M., Yue, W., Eischeid, A. C., Wang, J., & Santen, R. J. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006406030612 · Cited by 98
“Women with advanced breast cancer frequently respond to initial hormonal therapy with tumor regression but invariably experience regrowth approximately 12–18 months later [1].”
BackgroundSelf-citation
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study
Pyrhönen, S. O., Valavaara, R., Modig, H. G., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.375 · Cited by 98
Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-Fluorestradiol (FES)
Mankoff, D. A., Tewson, T. J., & Eary, J. F. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(97)00002-4 · Cited by 95
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients
Demers, L. M. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682744 · Cited by 95
“Inhibition of aromatase activity is currently a second line therapeutic alternative for the treatment of patients with hormone dependent forms of breast cancer [1].”
Background
Failure of Chloro-S-triazine-Derived Compounds to Induce Estrogen Receptor-Mediated Responsesin Vivoandin Vitro
Connor, K. T. (1996) · Fundamental and Applied Toxicology · doi:10.1006/faat.1996.0046 · Cited by 94
Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming, F., Hill, A., Mcdermott, E., O'Higgins, N., & Young, L. (2004) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2003-031048 · Cited by 102
“378 J Clin Endocrinol Metab, January 2004, 89(1):375–383 Fleming et al.”
BackgroundInfluential
Exposure to parabens at the concentration of maximal proliferative response increases migratory and invasive activity of human breast cancer cells in vitro
Khanna, S., Dash, P. R., & Darbre, P. D. (2014) · Journal of Applied Toxicology · doi:10.1002/jat.3003 · Cited by 92
“Nevertheless, ER+ tumours do still metastasize and reduction of oestrogen action through endocrine therapy using antioestrogen or aromatase inhibitors is known to reduce numbers of local and distant metastases (Santen et al., 1990) which suggests an effect on the metastatic process as well as on tumour growth.”
Background
Aromatase gene expression in adipose tissue: Relationship to breast cancer
Bulun, S. E., Mahendroo, M., & Simpson, E. R. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90274-7 · Cited by 94
In vivotranscription of a progesterone-responsive gene is specifically inhibited by a triplex-forming oligonucleotide
Ing, N. H., Beekman, J. M., Kessler, D. J., et al. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.12.2789 · Cited by 92
Comprehensive Pharmacology and Clinical Efficacy of Aromatase Inhibitors
Njar, V. C. O., & Brodie, A. M. H. (1999) · Drugs · doi:10.2165/00003495-199958020-00003 · Cited by 92
“Indeed, preclinical tests in mice demonstrated that rogletimide lacks the sedative and other CNS effects of aminoglutethimide.[126] In vivo in the rat, rabbit and in humans, 244 Njar & Brodie”
Background
Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients
Santen, R. J., Jeng, M., Wang, J., et al. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00151-0 · Cited by 90
Self-citation
Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment
BOSSCHE, H. V. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90328-g · Cited by 89
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
Birrell, S. N., Roder, D. M., Horsfall, D. J., Bentel, J. M., & Tilley, W. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1572 · Cited by 87
Aromatase inhibitors in ovulation induction
(2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-823028 · Cited by 87
“The main sources of circulating estrogens are the ovaries in premenopausal women and adipose tissue in postmenopausal women.(28,29) THE DEVELOPMENT OF AROMATASE INHIBITORS”
Background
Tracking progesterone receptor-mediated actions in breast cancer
Knutson, T. P., & Lange, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.010 · Cited by 91
Characterizing Tumors Using Metabolic Imaging: PET Imaging of Cellular Proliferation and Steroid Receptors
Mankoff, D. A., Dehdashti, F., & Shields, A. F. (2000) · Neoplasia · doi:10.1038/sj.neo.7900075 · Cited by 87
Structure−Activity Relationships of 17α-Derivatives of Estradiol as Inhibitors of Steroid Sulfatase
Boivin, R. P., Luu-The, V., Lachance, R., Labrie, F., & Poirier, D. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0001166 · Cited by 86
Celebrating 75 years of oestradiol
Simpson, E. R., & Santen, R. J. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0128 · Cited by 88
“Later the concept of hormone additive therapy ensued and women were treated successfully with oestrogens, androgens, and progestins (Santen et al. 1990).”
Self-citation
Progesterone receptor and the mechanism of action of progesterone antagonists
Edwards, D. P., Altmann, M., Marzo, A. M. D., et al. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00091-d · Cited by 85
Interaction between FGFR-2, STAT5, and Progesterone Receptors in Breast Cancer
Cerliani, J. P., Guillardoy, T., Giulianelli, S., Vaque, J. P., Gutkind, J. S., Vanzulli, S. I., Martins, R., Zeitlin, E., Lamb, C. A., & Lanari, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3074 · Cited by 85
“Two-thirds of breast cancers express estrogen (ER) and progesterone receptors (PR) at the time of diagnosis (1); most of these cancers arise in postmenopausal women with low levels of circulating hormones.”
Background
Energetic factors, ovarian steroids and the risk of breast cancer
Grazyna Jasienska, A., Thune, I., & Ellison, P. T. (2000) · European Journal of Cancer Prevention · doi:10.1097/00008469-200008000-00003 · Cited by 85
90 YEARS OF PROGESTERONE: Progesterone and progesterone receptors in breast cancer: past, present, future
Horwitz, K. B., & Sartorius, C. A. (2020) · Journal of Molecular Endocrinology · doi:10.1530/jme-20-0104 · Cited by 85
Inhibition of aromatase: insights from recent studies
Santen, R. J. (2003) · Steroids · doi:10.1016/s0039-128x(03)00096-5 · Cited by 83
Self-citation
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
Demers, L. M., Lipton, A., Harvey, H. A., Kambic, K. B., Grossberg, H., Brady, C., & Santen, R. J. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90283-3 · Cited by 83
Self-citation
Aryl Hydrocarbon Receptor-Mediated Antiestrogenicity in MCF-7 Cells: Modulation of Hormone-Induced Cell Cycle Enzymes
Wang, W., Smith, R., & Safe, S. H. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0782 · Cited by 81
Synthesis of an Estrogen Receptor β-Selective Radioligand: 5-[18F]Fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and Comparison of in Vivo Distribution with 16α-[18F]Fluoro-17β-estradiol
Yoo, J., Dence, C. S., Sharp, T. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050121f · Cited by 79
Administration of an aromatase inhibitor during the late follicular phase of gonadotropin-treated cycles in rhesus monkeys: effects on follicle development, oocyte maturation, and subsequent luteal function
Zelinski, M. B., Hess, D. L., Baughman, W. L., Molskness, T. A., Wolf, D. P., & Stouffer, R. L. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473415 · Cited by 83
Assessing the estrogenic and dio×in-like activities of chemicals and comple× mi×tures using in vitro recombinant receptor–reporter gene assays
Balaguer, P., Joyeu×, A., Denison, M. S., et al. (1996) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-74-2-216 · Cited by 79
“, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)), can also modulate estrogenic responses via mechanisms that are removed from the ER (Anazano et al. 1994; Demirpence et al. 1994; Fontana et al. 1990; Keller et al. 1995; Rubin et al. 1994; Safe et al. 1991a, 1991b; Santen et al. 1990; Segars et al. 1993).”
Background
Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen
Cathcart, C. K., Jones, S. E., Pumroy, C. S., Peters, G. N., Knox, S. M., & Cheek, J. H. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665698 · Cited by 77
“Depression has long been recognized as a possible side effect of tamoxifen, but only in recent years has it been given noteworthy status [6-8].”
Background
Biological rationale for endocrine therapy in breast cancer
Miller, W. R. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00044-7 · Cited by 77
Involvement of cyclic AMP response element binding protein (CREB) and estrogen receptor phosphorylation in the synergistic activation of the estrogen receptor by estradiol and protein kinase activators
Lazennec, G., Thomas, J. A., & Katzenellenbogen, B. S. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00060-7 · Cited by 77
“4 cancers, only in two-third of the cases is antiestrogen treatment effective [26-28].”
Background
Regulation of RARβ expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: Effect on growth inhibition and apoptosis induction
Li, Y., Dawson, M. I., Agadir, A., Lee, M., Jong, L., Hobbs, P. D., & Zhang, X.-K. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980105)75:1 · Cited by 94
Adaptive Hypersensitivity to Estrogen
Santen, R. J., Song, R. X.-D., Zhang, Z., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031207 · Cited by 75
Self-citation
Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems
Katzenellenbogen, B. S., Bhardwaj, B., Fang, H., Ince, B. A., Pakdel, F., Reese, J. C., Schodin, D. J., & Wrenn, C. K. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90055-2 · Cited by 74
Aromatase inhibitors ? mechanisms of steroidal inhibitors
Brueggemeier, R. W. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00682739 · Cited by 75
“Research summaries of aromatase inhibitors have been presented at the three international aromatase conferences [1-3], and several reviews have also been published [6-13].”
Background
High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa
Preston, S. R., Lf, W., Jones-Blackett, S., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.210 · Cited by 74
Estrogen Stimulation of Cell Migration Involves Multiple Signaling Pathway Interactions
Li, Y., Wang, J.-P., Santen, R. J., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1506 · Cited by 73
Self-citation
Effect of the High-Affinity Estrogen Receptor Ligand ICI 182,780 on the Rat Tibia
Sibonga, J. D., Dobnig, H., Harden, R., & Turner, R. T. (1998) · Endocrinology · doi:10.1210/endo.139.9.6172 · Cited by 74
5 -Reductases in Human Breast Carcinoma: Possible Modulator of in Situ Androgenic Actions
Suzuki, T., Darnel, A. D., Akahira, J., Ariga, N., Ogawa, S. A., Kaneko, C., Takeyama, J., Moriya, T., & Sasano, H. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7444 · Cited by 74
“Administration of androgens has been reported to result in the regression of some cases of breast carcinoma, but also to cause androgenic side-effects (5).”
Background
Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo
Koshizuka, K., Koike, M., Asou, H., et al. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006123819675 · Cited by 72
“and they have a significantly worse prognosis than those with estrogen receptors [24].”
Background
Inhibition of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor growth by aryl hydrocarbon receptor agonists
McDougal, A. J., Wilson, C., & Safe, S. H. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)00299-1 · Cited by 72
“A high percentage of initial mammary tumors are estrogen receptor (ER)-positive and respond to endocrine therapy [2–5].”
Background

Authors: SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C.
Affiliations: Pennsylvania State University (US)
Corresponding author: SANTEN, RICHARD J.
ORCID: SANTEN, RICHARD J.
Venue: Endocrine Reviews
Publisher: The Endocrine Society
Published: 1990-05
Volume: 11
Issue: 2
Pages: 221-265
ISSN: 0163-769X (ISSN-L)
1945-7189
DOI: 10.1210/edrv-11-2-221
OpenAlex: W2114712559
Cited by: 399
References: 0
Citations by year: 2026: 3 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 5 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 5 · 2013: 11 · 2012: 4
FWCI: 11.36
Type: journal article
Language: en
Open access: closed
Locations: Endocrine Reviews (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: breast cancer, endocrine therapy, hormone therapy, oophorectomy, adrenalectomy, hypophysectomy, androgens, estrogen, progestins, glucocorticoids, tumor regression, treatment selection
MeSH terms: Androgens, Breast Neoplasms, Estrogen Antagonists, Estrogens, Female, Glucocorticoids, Humans, Progestins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Endocrine Treatment of Breast Cancer in Women

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks